CClinicalTrials.gg
Not yet recruitingNCT07698704PFPSUpdated Jul 13, 2026

Popliteus Muscle Release Versus Patellofemoral Mobilization in Patellofemoral Pain Syndrome

An interventional study of Popliteus Muscle Release and Patellofemoral Mobilization in Patellofemoral Pain Syndrome, sponsored by Cairo University. Not yet recruiting. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Study summary

This study will be conducted to compare the effect of popliteus muscle release and patellofemoral mobilization on pain intensity, function, and quadriceps muscle strength in patients with patellofemoral pain syndrome?

Read the detailed description

The gradual development of diffuse anterior knee pain is characteristic of patellofemoral pain (PFP), which is made worse by activities that put stress on the patellofemoral joint, such as running, stair climbing, and squatting. While 23% of the overall population has PFP, athletes can have a prevalence of 35%.Patellofemoral pain syndrome (PFPS) is a widespread disease with a significant impact on society, with a 22.7% prevalence in the general population.The patella is the largest sesamoid bone in the body and acts as a fulcrum to improve the mechanical advantage of the quadriceps. In full knee extension the patella does not articulate with the femoral condyles, and related to the lack of articular congruency, is able to glide more freely. The inferior patellar facet first contacts the femoral condyle around 20-30o of knee flexion.The popliteus tendon is a primary stabilizer of external knee rotation and has been described as the "fifth ligament of the knee." Injuries involving the posterolateral corner of the knee commonly involve the popliteus tendon; isolated injury to the popliteus tendon is relatively rare and usually involves a rotatory injury mechanism and symptoms of instability and pain.Myofascial release has been shown to improve pain, range of motion, and functional outcomes in individuals with knee disorders. By targeting fascial restrictions around the quadriceps, hamstrings, iliotibial band, and peri-patellar tissues, myofascial techniques help reduce tissue stiffness and abnormal tension that may contribute to altered patellar tracking and joint loading.Patellofemoral mobilization is considered an important intervention in the management of PFPS, particularly in patients presenting with pain, stiffness, or altered patellar tracking.Although both techniques are used to reduce anterior knee pain and improve function, current evidence is insufficient to determine which intervention is more effective. Therefore, further randomized controlled trials are needed to compare their effects on pain and functional outcomes in individuals with PFPS.

02

Conditions studied

  • Patellofemoral Pain Syndrome

Keywords

  • Popliteus Muscle Release
  • Patellofemoral Mobilization
  • Patellofemoral Pain Syndrome
03

In context

Patellofemoral Pain Syndrome

295 studies on the registry are indexed under Patellofemoral Pain Syndrome; 75 are open to participants now.

This study's planned enrollment of 48 is close to the median of 45 across 242 interventional studies indexed under Patellofemoral Pain Syndrome.

Browse Patellofemoral Pain Syndrome studies →

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male and female participants aged 18-30 years.
  • minimum history of 3 months of unilateral PFP.
  • pain intensity score of ≥3 on a 10-cm Visual Analog Scale (VAS) for worst pain experienced during the previous week.
  • Pain reproduced during at least two of the following functional activities: stair ascent or descent, running, hopping, prolonged sitting, squatting, or kneeling.
  • Presence of pain on at least one of the following clinical tests: patellar compression test or palpation of the patellar facets.

Exclusion criteria

Exclusion Criteria:

  • Clinical, x-ray, or MRI findings indicative of other specific pathology including osteoarthritis, meniscal, ligament or cartilage injury, apophysitis.
  • Recurrent patellar subluxation or dislocation.
  • Cortisone use over an extended period of time.
  • Previous surgery to the knee joint; trauma to the knee joint affecting the presenting clinical condition.
  • Lower limb deformities.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Popliteus Muscle Release

    Sixteen patients with patellofemoral pain syndrome will receive popliteus muscle release. plus traditional physical therapy three times a week for 4 weeks.

    Other: Popliteus Muscle Release · Other: traditional therapy

  • Experimental
    Patellofemoral Mobilization

    Sixteen patients with patellofemoral pain syndrome will receive patellofemoral mobilization plus traditional physical therapy three times a week for 4 weeks.

    Other: Patellofemoral Mobilization · Other: traditional therapy

  • Active comparator
    traditional therapy

    Sixteen patients with patellofemoral pain syndrome will receive traditional physical therapy three times a week for 4 weeks.

    Other: traditional therapy

Interventions

  • OtherPopliteus Muscle Release

    the participant will lie supine and relaxed on a treatment bench. The therapist will begin the treatment by flexing the participant's knee to approximately 15-25 degrees. Then, the therapist will apply pressure to the popliteus muscle while simultaneously extending the knee to approximately 5 degrees of flexion. When the knee is extended, the pressure will be released. The therapist will repeat this procedure for up to 2 minutes plus tradional therapy

  • OtherPatellofemoral Mobilization

    Following the clinical guidelines established by Brukner and Khan, the mobilization will be performed with the patient in a supine position to ensure complete relaxation of the quadriceps musculature, thereby minimizing joint compressive forces. The intervention will include multidirectional glides tailored to specific functional deficits:Superior glides,Inferior glides,Medial-lateral excursions and tilt mobilization.Each mobilization will be applied as a gentle sustained glide for duration of 30 to 60 seconds per repetition

  • Othertraditional therapy

    patients will receive quadriceps muscle strength, hip extension strength, hamstring stretch.

06

What researchers measure

Primary outcomes

  1. pain intensity

    The scale used will be the visual analogue scale (VAS), which consists of a line, usually 10 cm long, the patient will be instructed to place a vertical mark on to indicate his/ her pain, ranging from no pain or discomfort (0), to the worst pain that could possibly feel

    Time frame: up to four weeks

Secondary outcomes

  1. knee disability

    The Kujala Arabic version will be used to assess knee disability. it is 13 items on the scale are used to assess subjective symptoms and functional restrictions. A score can have a minimum of 0 points or a maximum of 100 points.Lower scores reflect greater pain and disability

    Time frame: up to four weeks

  2. quadriceps muscle strength

    A handheld dynamometer will be used to assess quadrecips muscle strength

    Time frame: up to four weeks

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07698704
Lead sponsor
Cairo University
Responsible party
Mohamed Abdelalim Bahig (principle investigator : mohamed abdelalim bahig, Cairo University) — Principal investigator
First posted
Jul 13, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Jul 13, 2026

Study contacts

mohamed Bahig, master
Contact
mohamed.bahig@the.suezuni.edu.eg
0 11 41644884

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion